Cleveland Diagnostics Names New CEO Following FDA Approval of Prostate Cancer Test
The new leader brings over 30 years of industry experience from Bayer, Siemens, and Ortho Clinical Diagnostics to lead commercial expansion.
Read More
Search Results for: prostate cancer
Valley Diagnostics Licenses Biomarker Technology for Cancer, Disease Detection
Valley Diagnostics has secured exclusive global rights to develop point-of-care lateral flow tests for prostate cancer, lung cancer, and animal diseases, with product rollout planned for 2026.
Read More
Tempus Launches AI-Powered Digital Pathology Suite for Biomarker Prediction
Tempus has introduced Paige Predict, an AI-powered pathology suite that analyzes H&E slides to predict 123 biomarkers across 16 cancer types when tissue samples are insufficient.
Read More
Whole-Genome Sequencing Algorithm Shows Promise for PARP Inhibitor Selection
Weill Cornell Medicine researchers report a whole-genome sequencing algorithm may identify more patients for PARP inhibitor cancer therapies than current commercial tests, according to a study in Communications Medicine.
Read More
CTC Counts Show Value in Guiding Metastatic Breast Cancer Treatment Decisions
Researchers found that circulating tumor cell counts stratified patients by disease aggressiveness and were associated with differing outcomes following endocrine versus combination therapy.
Read More